查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1747050

日本抗真菌藥物市場報告（按藥物類別（唑類、棘白菌素類、多烯類、烯丙胺類等）、適應症（皮癬菌病、曲霉病、念珠菌病等）和地區分類）2025-2033

Japan Antifungal Drugs Market Report by Drug Classe (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 118 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2024年，日本抗真菌藥物市場規模達10.8億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到16.3億美元，2025-2033年期間的複合年成長率（CAGR）為4.47%。真菌感染病例的增加，歸因於多種因素，例如免疫功能低下人群的增加、人口老化、免疫抑制藥物的廣泛使用等，正在推動市場的發展。

抗真菌藥物是用來對抗人類、動物和植物真菌感染的藥物化合物。真菌感染的症狀從輕微的皮膚病到嚴重的、危及生命的全身性疾病。這些藥物透過靶向真菌細胞生長和功能的各個方面發揮作用，抑制其複製和擴散能力。抗黴菌藥物有多種類別，包括唑類、多烯類、棘白菌素類和烯丙胺類。唑類，例如氟康唑和伊曲康唑，會干擾真菌細胞膜的合成。多烯類，例如兩性黴素B，會直接破壞真菌細胞膜。棘白菌素類，包括卡泊芬淨，會抑制細胞壁的形成。烯丙胺類，例如特比萘芬，會干擾真菌酶的活性。選擇合適的抗真菌藥物取決於感染的類型和嚴重程度，以及患者的健康狀況。有些抗真菌藥物可在非處方藥中外用，而有些則需要處方才能用於全身感染。依照規定使用這些藥物至關重要，以確保有效性並最大限度地降低出現抗藥性真菌菌株的風險。

日本抗真菌藥物市場趨勢：

日本抗真菌藥物市場有望實現大幅成長，這主要得益於幾個相互關聯的因素。首先，真菌感染發生率的上升是關鍵促進因素。隨著真菌病原體的抗藥性增強，對創新抗真菌療法的需求也日益增加。此外，老齡人口的成長（通常免疫系統較弱）也增加了老年人對真菌感染的易感性，這進一步推動了市場擴張。其次，醫學研究和生物技術的進步為新型抗真菌藥物的開發鋪平了道路。對真菌生物學理解的突破以及新藥物靶點的發現，帶來了源源不絕的創新療法。因此，製藥公司正大力投資研發，促進市場成長。此外，各國政府和醫療機構在控制真菌感染傳播方面提供的資金和優惠政策支持不斷增加，預計將在預測期內推動日本抗真菌藥物市場的發展。

日本抗真菌藥物市場細分：

藥物類別洞察：

  • 唑類
    • 伏立康唑（Vfend）
    • 泊沙康唑（Noxafil）
    • 克黴唑（凱妮汀）
    • 艾沙康唑（Cresemba）
    • 其他
  • 棘白菌素類
    • 卡泊芬淨（Cancidas）
    • 米卡芬淨（Mycamine/ Funguard）
    • 其他
  • 多烯類
    • 兩性黴素（AmBisome）
    • 其他
  • 烯丙胺
    • 特比萘芬（Lamisil）
    • 其他
  • 其他

指示見解：

  • 皮癬菌病
  • 麴菌病
  • 念珠菌病
    • 侵襲性念珠菌病
    • 外陰陰道念珠菌病（VVC）
    • 口腔/咽喉/食道念珠菌病
    • 其他
  • 其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

  • 日本抗真菌藥物市場迄今表現如何，未來幾年將如何表現？
  • COVID-19 對日本抗真菌藥物市場有何影響？
  • 日本抗真菌藥物市場按藥物類別分類是怎樣的？
  • 日本抗真菌藥物市場根據適應症的分佈是怎樣的？
  • 日本抗黴菌藥物市場的價值鏈分為哪些階段？
  • 日本抗真菌藥物的關鍵促進因素和挑戰是什麼？
  • 日本抗黴菌藥物市場的結構是怎麼樣的？主要參與者是誰？
  • 日本抗黴菌藥物市場的競爭程度如何？

本報告回答的關鍵問題：

  • 日本抗真菌藥物市場迄今表現如何，未來幾年將如何表現？
  • COVID-19 對日本抗真菌藥物市場有何影響？
  • 日本抗真菌藥物市場按藥物類別分類是怎樣的？
  • 日本抗真菌藥物市場根據適應症的分佈是怎樣的？
  • 日本抗黴菌藥物市場的價值鏈分為哪些階段？
  • 日本抗真菌藥物的關鍵促進因素和挑戰是什麼？
  • 日本抗黴菌藥物市場的結構是怎麼樣的？主要參與者是誰？
  • 日本抗黴菌藥物市場的競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：日本抗黴菌藥物市場 - 簡介

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭情報

第5章：日本抗黴菌藥物市場概況

  • 歷史與當前市場趨勢（2019-2024）
  • 市場預測（2025-2033）

第 6 章：日本抗真菌藥物市場 - 細分：按藥物類別

  • 唑類
    • 概述
    • 市場區隔
      • 伏立康唑（Vfend）
      • 泊沙康唑（Noxafil）
      • 克黴唑（凱妮汀）
      • 艾沙康唑（Cresemba）
      • 其他
  • 棘白菌素類
    • 概述
    • 市場區隔
      • 卡泊芬淨（Cancidas）
      • 米卡芬淨（Mycamine/ Funguard）
      • 其他
  • 多烯類
    • 概述
    • 市場區隔
      • 兩性黴素（AmBisome）
      • 其他
  • 烯丙胺
    • 概述
    • 市場區隔
      • 特比萘芬（Lamisil）
      • 其他
  • 其他

第7章：日本抗黴菌藥物市場-細分：按適應症

  • 皮癬菌病
    • 概述
  • 麴菌病
    • 概述
  • 念珠菌病
    • 概述
    • 市場區隔
      • 侵襲性念珠菌病
      • 碳酸鈣
      • 外陰陰道念珠菌病（VVC）
      • 口腔/咽喉/食道念珠菌病
      • 其他
  • 其他

第 8 章：日本抗黴菌藥物市場 - 競爭格局

  • 概述
  • 市場結構
  • 市場參與者定位
  • 最佳獲勝策略
  • 競爭儀錶板
  • 公司評估象限

第9章：關鍵參與者簡介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第10章：日本抗真菌藥物市場-產業分析

  • 促進因素、限制因素和機遇
    • 概述
    • 驅動程式
    • 限制
    • 機會
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價值鏈分析

第 11 章：附錄

簡介目錄
Product Code: SR112025A18738

Japan antifungal drugs market size reached USD 1.08 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1.63 Billion by 2033, exhibiting a growth rate (CAGR) of 4.47% during 2025-2033. The increasing cases of fungal infections, attributed to several factors, such as a growing population of immunocompromised individuals, aging people, the widespread use of immunosuppressive drug, etc., are driving the market.

Antifungal drugs are pharmaceutical compounds designed to combat fungal infections in humans, animals, and plants. Fungal infections can range from mild skin conditions to severe, life-threatening systemic illnesses. These drugs work by targeting various aspects of fungal cell growth and function, inhibiting their ability to replicate and spread. There are several classes of antifungal drugs, including azoles, polyenes, echinocandins, and allylamines. Azoles, such as fluconazole and itraconazole, interfere with fungal cell membrane synthesis. Polyenes, like amphotericin B, disrupt fungal cell membranes directly. Echinocandins, including caspofungin, inhibit cell wall formation. Allylamines, such as terbinafine, interfere with fungal enzyme activity. Choosing the appropriate antifungal drug depends on the type and severity of the infection, as well as the patient's health status. Some antifungals are available over-the-counter for topical use, while others require a prescription for systemic infections. It's crucial to use these drugs as prescribed to ensure effectiveness and minimize the risk of drug-resistant fungal strains emerging.

Japan Antifungal Drugs Market Trends:

The antifungal drugs market in Japan is poised for significant growth, primarily due to several interconnected factors. Firstly, the rising incidence of fungal infections serves as a crucial driver. As fungal pathogens become more resistant, the demand for innovative antifungal therapies intensifies. Moreover, the growing elderly population, often with compromised immune systems, increases susceptibility to fungal infections, further propelling market expansion. Secondly, advancements in medical research and biotechnology have paved the way for novel antifungal drug development. Breakthroughs in understanding fungal biology and the discovery of new drug targets have led to a steady influx of innovative therapies. Consequently, pharmaceutical companies are investing heavily in R&D, fostering market growth. Additionally, the rising support from various governments and healthcare organizations in the form of funding and favorable policies to control the spread of fungal infections is expected to drive the antifungal drugs market in Japan during the forecast period.

Japan Antifungal Drugs Market Segmentation:

Drug Class Insights:

  • Azoles
    • Voriconazole (Vfend)
    • Posaconazole (Noxafil)
    • Clotrimazole (Canesten)
    • Isavuconazole (Cresemba)
    • Others
  • Echinocandins
    • Caspofungin (Cancidas)
    • Micafungin (Mycamine/ Funguard)
    • Others
  • Polyenes
    • Amphotericin (AmBisome)
    • Others
  • Allylamines
    • Terbinafine (Lamisil)
    • Others
  • Others

Indication Insights:

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
    • Invasive Candidiasis
    • Vulvovaginal Candidiasis (VVC)
    • Mouth/Throat/Esophageal Candidiasis
    • Others
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan antifungal drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan antifungal drugs market?
  • What is the breakup of the Japan antifungal drugs market on the basis of drug class?
  • What is the breakup of the Japan antifungal drugs market on the basis of indication?
  • What are the various stages in the value chain of the Japan antifungal drugs market?
  • What are the key driving factors and challenges in the Japan antifungal drugs?
  • What is the structure of the Japan antifungal drugs market and who are the key players?
  • What is the degree of competition in the Japan antifungal drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Antifungal Drugs Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Antifungal Drugs Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Antifungal Drugs Market - Breakup by Drug Class

  • 6.1 Azoles
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Voriconazole (Vfend)
      • 6.1.3.2 Posaconazole (Noxafil)
      • 6.1.3.3 Clotrimazole (Canesten)
      • 6.1.3.4 Isavuconazole (Cresemba)
      • 6.1.3.5 Others
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Echinocandins
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 Caspofungin (Cancidas)
      • 6.2.3.2 Micafungin (Mycamine/ Funguard)
      • 6.2.3.3 Others
    • 6.2.4 Market Forecast (2025-2033)
  • 6.3 Polyenes
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Segmentation
      • 6.3.3.1 Amphotericin (AmBisome)
      • 6.3.3.2 Others
    • 6.3.4 Market Forecast (2025-2033)
  • 6.4 Allylamines
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Segmentation
      • 6.4.3.1 Terbinafine (Lamisil)
      • 6.4.3.2 Others
    • 6.4.4 Market Forecast (2025-2033)
  • 6.5 Others
    • 6.5.1 Historical and Current Market Trends (2019-2024)
    • 6.5.2 Market Forecast (2025-2033)

7 Japan Antifungal Drugs Market - Breakup by Indication

  • 7.1 Dermatophytosis
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Aspergillosis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Candidiasis
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Segmentation
      • 7.3.3.1 Invasive Candidiasis
      • 7.3.3.2 Calcium Carbonate
      • 7.3.3.3 Vulvovaginal Candidiasis (VVC)
      • 7.3.3.4 Mouth/Throat/Esophageal Candidiasis
      • 7.3.3.5 Others
    • 7.3.4 Market Forecast (2025-2033)
  • 7.4 Others
    • 7.4.1 Historical and Current Market Trends (2019-2024)
    • 7.4.2 Market Forecast (2025-2033)

8 Japan Antifungal Drugs Market - Competitive Landscape

  • 8.1 Overview
  • 8.2 Market Structure
  • 8.3 Market Player Positioning
  • 8.4 Top Winning Strategies
  • 8.5 Competitive Dashboard
  • 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

  • 9.1 Company A
    • 9.1.1 Business Overview
    • 9.1.2 Product Portfolio
    • 9.1.3 Business Strategies
    • 9.1.4 SWOT Analysis
    • 9.1.5 Major News and Events
  • 9.2 Company B
    • 9.2.1 Business Overview
    • 9.2.2 Product Portfolio
    • 9.2.3 Business Strategies
    • 9.2.4 SWOT Analysis
    • 9.2.5 Major News and Events
  • 9.3 Company C
    • 9.3.1 Business Overview
    • 9.3.2 Product Portfolio
    • 9.3.3 Business Strategies
    • 9.3.4 SWOT Analysis
    • 9.3.5 Major News and Events
  • 9.4 Company D
    • 9.4.1 Business Overview
    • 9.4.2 Product Portfolio
    • 9.4.3 Business Strategies
    • 9.4.4 SWOT Analysis
    • 9.4.5 Major News and Events
  • 9.5 Company E
    • 9.5.1 Business Overview
    • 9.5.2 Product Portfolio
    • 9.5.3 Business Strategies
    • 9.5.4 SWOT Analysis
    • 9.5.5 Major News and Events

10 Japan Antifungal Drugs Market - Industry Analysis

  • 10.1 Drivers, Restraints, and Opportunities
    • 10.1.1 Overview
    • 10.1.2 Drivers
    • 10.1.3 Restraints
    • 10.1.4 Opportunities
  • 10.2 Porters Five Forces Analysis
    • 10.2.1 Overview
    • 10.2.2 Bargaining Power of Buyers
    • 10.2.3 Bargaining Power of Suppliers
    • 10.2.4 Degree of Competition
    • 10.2.5 Threat of New Entrants
    • 10.2.6 Threat of Substitutes
  • 10.3 Value Chain Analysis

11 Appendix